Health TrialsbyHealthPanel

Genetic and Molecular Characterization of Nervous System Lesions

ConditionsBrain TumorBrain Lesion (General)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Primary and secondary brain tumors, the leading cause of death from cancer before the age of 35, represent a complex and heterogeneous group of pathologies with a generally poor prognosis. Knowledge of these tumors has made enormous strides thanks to access to biological samples, leading to a much more robust, reliable and precise histo-pronostic classification, but also, increasingly, to the identification of theranostic targets.

Despite these advances, there is a real need to refine diagnostic and prognostic classification, identify the biological mechanisms involved in the formation and progression of these pathologies, develop new targeted strategies, and devise minimally invasive follow-up methods (liquid biopsies).

In addition, certain non-tumoral brain lesions (e.g. malformations) can be similarly classified according to their molecular and mutational profile.

This project aims to make a decisive contribution to these objectives.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Any patient operated on for a brain lesion (e.g. tumors: glioma, LCPSNC, meningioma, or rare tumor) and/or followed up for one of these pathologies.

Age ≥ 18 years

Consent or non-opposition of the patient or his/her legal representative (guardian) to participate in the study.

Disqualifiers

None

Trial population

Adult patients with brain lesions, including pregnant women (e.g. tumors: patient with glioma, but also with primary brain lymphoma, meningioma, or primary brain tumor of a rare subtype, secondary tumor).

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Prospective Biological Collection

    Genetic

    All samples that can be collected at each visit : * Saliva sampling (added by the research) * Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care) * Urine and stool samples (added by the research) * CSF sample residues (added by the research if lumbar punction in routine care) * Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)

  • Retrospective Biological Collection

    Genetic

    Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)

Treatment groups

10,000 Participants
are divided into 3 treatment groups
Group A: Group 12 interventions
Group B: Group 22 interventions
Group C: Group 31 intervention

Trial outcomes

Primary outcomes

1

Study the clinical markers with the evolution of brain lesions.

Study of patients' disease-related data in their medical records

Time frame
10 years
2

Study the biological markers with the evolution of brain lesions.

Study blood, saliva, urine, stool and CSF samples

Time frame
10 years
3

Study the anatomopathological markers with the evolution of brain lesions.

Study of cerebral lesion tissues

Time frame
10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Source ClinicalTrials.gov
Apply now